About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNCT05662345

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Lead sponsor: Menarini Silicon Biosystems, INC•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Menarini Silicon Biosystems, INC

Collaborators

Medex15

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
•2. ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
•3. Measurable and/or non-measurable disease is allowed
•4. Male or female breast cancer is allowed
•5. Age \> 18 years
•6. Willingness to provide mandatory blood specimens
•7. Willing to return to enrolling institution for follow up imaging at least once

Exclusion Criteria

•1. Life expectancy of ≤ 6 months
•2. Inability to provide blood samples based on the judgment of the treating provider

Related studies

Exercise in Metastatic Breast Cancer: EMBody

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer

RECRUITINGPhase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, and more

RECRUITINGPhase 2

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

NCT05660083 · HER2-negative Breast Cancer, Metastatic Breast Cancer, and more

RECRUITINGPhase 3

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

NCT07354022 · Locally Advanced or Metastatic Breast Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 17, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment65

Start dateDec 2022

Last updatedMar 17, 2026

Condition

Metastatic Breast Cancer

Locations shown

Mayo Clinic Health System Albert Lea

Albert Lea, Minnesota

Mayo Clinic Health System Mankato

Mankato, Minnesota

Mayo Clinic

Rochester, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions